SCHEMBL4504903

SCHEMBL4504903

O=C(O)C1CNCC(NS(=O)(=O)c2ccccc2Cl)C1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
REN P00797 4/20 0.47
HTR1A P08908 1/20 0.44
HTR7 P34969 1/20 0.44
SLC6A11 P48066 2/20 0.41
POLB P06746 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
ITGAV P06756 1/20 0.40
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
FAAH O00519 1/20 0.38
DPP4 P27487 1/20 0.38
LIPE Q05469 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504905 1.00 ALDH1A1 (0.56) ALDH1A1L3MBTL1RENHTR1AHTR7
SCHEMBL4498092 0.90 REN (0.49) ALDH1A1L3MBTL1RENSLC6A11ITGAV
SCHEMBL4498089 0.90 REN (0.49) ALDH1A1L3MBTL1RENSLC6A11ITGAV
SCHEMBL4499022 0.86 HDAC8 (0.46) ALDH1A1L3MBTL1RENSLC6A11ITGAV
SCHEMBL4499020 0.86 HDAC8 (0.46) ALDH1A1L3MBTL1RENSLC6A11ITGAV
SCHEMBL4499002 0.86 MAPK1 (0.44) ALDH1A1L3MBTL1RENSLC6A11
SCHEMBL4499004 0.86 MAPK1 (0.44) ALDH1A1L3MBTL1RENSLC6A11
SCHEMBL4499115 0.84 REN (0.44) ALDH1A1RENSLC1A3SLC1A2SLC1A1
SCHEMBL4499118 0.84 REN (0.44) ALDH1A1RENSLC1A3SLC1A2SLC1A1
SCHEMBL4508089 0.83 REN (0.59) ALDH1A1RENSLC6A11DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP disclosed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 ALDH1A1 39/4885L3MBTL1 3191/4885REN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.